EICHORCondition: Primary Immune Deficiency · Sponsor: Octapharma
Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Octapharma Research Site | Irvine, California, United States | — |
| Octapharma Research Site | Centennial, Colorado, United States | — |
| Octapharma Research Site | Port Saint Lucie, Florida, United States | — |
| Octapharma Research Site | St. Petersburg, Florida, United States | — |
| Octapharma Research Site | Chicago, Illinois, United States | — |
| Octapharma Research Site | Overland Park, Kansas, United States | — |
| Octapharma Research Site | Louisville, Kentucky, United States | — |
| Octapharma Research Site | White Marsh, Maryland, United States | — |
| Octapharma Research Site | Kansas City, Missouri, United States | — |
| Octapharma Research Site | Omaha, Nebraska, United States | — |
| Octapharma Research Site | Leipzig, Germany | — |
| Octapharma Research Site | Munich, Germany | — |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04640142